Vertex shares shoot up, adding $8B in market cap after cystic fibrosis triples 'knocked it out of the park'
Vertex came out of the chute after the market closed on Tuesday boasting about the efficacy data their researchers are seeing in a range of three Phase I and II studies for its new triple combos for cystic fibrosis. The data are still early but clearly bode well for Vertex, which is working hard to cast a far wider net among cystic fibrosis patients who have achieved modest but significant gains with their lead drug Kalydeco, which has won a sharp kickback from payers over its hefty price.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
